234108-73-7

Basic information

• Product Name: 4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98
• Synonyms: 4-Amino-2-chloropyridine, 4-BOC protected 98%;4-(Boc-aMino)-2-chloropyr...;N-tert-butyl-N-(2-chloropyridin-3-yl)carbaMate;tert-butyl 2-chloropyridin-4-ylcarbaMate Molecular;tert-Butyl (2-chloropyridin-4-yl)carbamate, 2-Chloro-4-(tert-butoxycarbonyl)pyridine;tert-butyl N-(2-chloropyridin-4-yl)carbamate;4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98;4-Amino-2-chloropyridine, N-BOC protected 98%
• CAS NO: 234108-73-7
• Molecular Formula: C₁₀H₁₃ClN₂O₂
• Molecular Weight: 228.678
• Product Categories: Amines;blocks;Pyridines;Pyridine series
• Mol File: 234108-73-7.mol

Chemical Properties

• Melting Point: 173-175
• Boiling Point: 282.245 °C at 760 mmHg
• Flash Point: 124.498 °C
• Appearance: /
• Density: 1.245 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 11.97±0.70(Predicted)
• CAS DataBase Reference: 4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98(234108-73-7)
• EPA Substance Registry System: 4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98(234108-73-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 234108-73-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98 is used as a reactant for the preparation of inter-domain stabilizers for allosteric Akt inhibitors. Akt, also known as protein kinase B, is a serine/threonine-specific protein kinase that plays a critical role in cellular survival, growth, and angiogenesis. Inhibition of Akt has been shown to have potential therapeutic benefits in various diseases, including cancer, making it an important target for drug development.
Akt Inhibitors:
4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98 is used as a key component in the synthesis of inter-domain stabilizers for allosteric Akt inhibitors. These inhibitors modulate the activity of Akt by binding to a specific site on the protein, leading to a conformational change that prevents its activation. This, in turn, disrupts the signaling pathways involved in cell survival and proliferation, making it a promising approach for the treatment of cancer and other diseases associated with aberrant Akt activity.
Drug Development:
In addition to its role in the synthesis of Akt inhibitors, 4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98 can also be utilized in the development of other bioactive molecules and pharmaceuticals. Its unique chemical structure allows for further functionalization and modification, enabling the creation of novel compounds with potential applications in various therapeutic areas.
Research and Development:
4-AMINO-2-CHLOROPYRIDINE, N-BOC PROTECTED 98 is also used as a valuable research tool in the field of medicinal chemistry. Its availability and reactivity make it an attractive candidate for the synthesis of new compounds and the exploration of novel chemical reactions. This contributes to the ongoing efforts in drug discovery and the development of innovative therapeutic strategies to address unmet medical needs.

InChI:InChI=1/C10H13ClN2O2/c1-10(2,3)15-9(14)13-7-4-5-12-8(11)6-7/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 14432-12-3 4-Amino-2-chloropyridine 
• 762-75-4 tert-butyl formate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73583-37-6 2-chloro-4-bromopyridine 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 234108-74-8 (2-chloro-3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 
• 849751-29-7 C₁₇H₁₈ClFN₂O₂ 
• 893422-47-4 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one 
• 917363-87-2 4-(9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)benzaldehyde 
• 917363-89-4 4-(3-methyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)benzaldehyde 
• 917364-04-6 4-[3-(hydroxymethyl)-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl]benzaldehyde 

Relevant articles and documents

Selective palladium-catalysed amination of 4-chloropyridines with benzylamines using the Josiphos ligand

A synthetic strategy for the synthesis of a library of 4-N-benzylamino-2-N-phenyl-pyridines is herein described. The approach involves a Pd-assisted cross-coupling of a 4-chloro-N-phenylpyridin-2-amine intermediate with a range of benzylamines. A variety of ligands were screened, the most successful being the Josiphos ligand, which gave the desired products in good to moderate yields. The reactions occur quickly, within 30 min, with full conversion of the intermediate into the desired product.

HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS

The present invention provides heterocyclic compounds of formula (I), which are therapeutically useful as CBP/EP300 inhibitors. These compounds are useful in the treatment and/or prevention of diseases or disorders mediated by CBP and/or EP300 in an individual. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer, an N-oxide or an ester thereof.

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

The Ser/Thr kinase Akt (Protein Kinase B/PKB) is a master switch in cellular signal transduction pathways. Its downstream signaling influences cell proliferation, cell growth, and apoptosis, rendering Akt a prominent drug target. The unique activation mechanism of Akt involves a change of the relative orientation of its N-terminal pleckstrin homology (PH) and the kinase domain and makes this kinase suitable for highly specific allosteric modulation. Here we present a unique set of crystal structures of covalent-allosteric interdomain inhibitors in complex with full-length Akt and report the structure-based design, synthesis, biological and pharmacological evaluation of a focused library of these innovative inhibitors.

Pd-catalyzed amidation of aryl(Het) halides with tert-butyl carbamate

Pd-catalyzed cross-coupling reaction of tert-butyl carbamate with various aryl(Het) halides with Cs2CO3 as base in 1,4-dioxane as solvent was investigated, which resulted in the formation of the desired compounds in moderate to excellent yields.

Rearrangement of N,N-di-tert-butoxycarbonylpyridin-4-amines and formation of polyfunctional pyridines

(Chemical Equation Presented) N,N-Di-tert-butoxycarbonylpyridin-4-amines were found to be rearranged to tert-butyl 4-(tert-butoxycarbonylamino) nicotinates by treatment with LDA in THF.

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors

This paper describes the improvement of cell potency in a class of allosteric Akt 1 and 2 inhibitors. Key discoveries include identifying the solvent exposed region of the molecule and appending basic amines to enhance the physiochemical properties of the

NOVEL COMPOUNDS THAT MODULATE PPARγ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

The invention relates to novel compounds corresponding to the general formula (I) below: and also to the method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also

INHIBITORS OF AKT ACTIVITY

The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and method

INHIBITORS OF AKT ACTIVITY

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

INHIBITORS OF AKT ACTIVITY

The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and method